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Abstract
Objectives: To assess the effectiveness of neuraminidase inhibitors for use in rapid
containment of influenza.
Method: We conducted a systematic review and meta-analysis in accordance with
the PRISMA statement. Healthcare databases and sources of grey literature were
searched up to 2012 and records screened against protocol eligibility criteria. Data
extraction and risk of bias assessments were performed using a piloted form.
Results were synthesised narratively and we undertook meta-analyses to calculate
pooled estimates of effect, statistical heterogeneity and assessed publication bias.
Findings: Nine randomised controlled trials (RCTs) and eight observational studies
met the inclusion criteria. Neuraminidase inhibitors provided 67 to 89% protection
for individuals following prophylaxis. Meta-analysis of individual protection showed
a significantly lower pooled odds of laboratory confirmed seasonal or influenza
A(H1N1)pdm09 infection following oseltamivir usage compared to placebo or no
therapy (n58 studies; odds ratio (OR)50.11; 95% confidence interval (CI)50.06 to
0.20; p,0.001; I2558.7%). This result was comparable to the pooled odds ratio for
individual protection with zanamivir (OR50.23; 95% CI 0.16 to 0.35). Similar point
estimates were obtained with widely overlapping 95% CIs for household protection
with oseltamivir or zanamivir. We found no studies of neuraminidase inhibitors to
prevent population-wide community transmission of influenza.
Conclusion: Oseltamivir and zanamivir are effective for prophylaxis of individuals
and households irrespective of treatment of the index case. There are no data
which directly support an effect on wider community transmission.
Protocol Registry: PROSPERO registration number: CRD42013003880
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Introduction
Influenza is a major public health concern, carrying a substantial global disease
burden. Annually, an estimated 5% to 10% of adults and 20% to 30% of children
are infected worldwide, with up to one million associated deaths [1]. The
incubation period for influenza averages two days (range: one to four days) [2]
and the mean serial interval is two to four days [3]. Consequently, influenza easily
spreads rapidly through communities. Vaccination is known to be the most
effective strategy for the prevention of influenza but in so many outbreak
scenarios inadequacy of vaccine coverage or effectiveness, resources shortages
(affordability) and urgency of the need for intervention make control with vaccine
suboptimal. The high rate of antigenic drift means that vaccines must be re-
formulated each year with the potential for imperfect matching between
circulating influenza virus and vaccine strains [4]. Consequently, many
governments stockpile antivirals, most notably, neuraminidase inhibitors, as a
precaution and in preparation against influenza epidemics/pandemics. It is argued
that reducing viral shedding with antiviral drugs may reduce infectivity and
thereby make onward transmission of influenza less likely [5]. It has been
suggested that if this phenomenon occurs in a widespread fashion, community
transmission may be reduced [6].
Previous systematic reviews have demonstrated that pre- and post-exposure
prophylaxis with neuraminidase inhibitors protects against laboratory confirmed
influenza at individual and household levels [7–13] but these considered only
randomised controlled trials (RCTs) of seasonal influenza conducted prior to the
2009 influenza A(H1N1) pandemic. The latest Cochrane Collaboration review on
neuraminidase inhibitors for preventing and treating influenza in healthy adults
and children was based on randomised, placebo controlled trials on adults and
children with confirmed or suspected exposure to seasonal influenza, conducted
primarily at individual and household levels [14]. Thus, the data from
observational studies pertaining to transmission have not yet been summarised,
and less is known about the impact of neuraminidase inhibitors for community
protection against pandemic and avian influenza.
Modelling studies predicated on assumptions made from clinical studies in
mainly household settings offer evidence that widespread rapid deployment of
antiviral drugs around the point source of an emergent pandemic could reduce
transmission and may result in containment at source [15, 16]. This concept
forms the nucleus of the current World Health Organization (WHO) Rapid
Containment Protocol, involving the establishment of a ‘containment zone’ [4]
around the locus of emergence of a novel influenza virus, within which all
asymptomatic residents will be given neuraminidase inhibitor prophylaxis for 20
days, combined with voluntary quarantine for contacts of cases, hand hygiene,
social distancing and perimeter control [17]. Despite modelling simulations, it
remains unclear if the findings at household level can truly be replicated at wider
community level as envisaged in the Rapid Containment Protocol [18].
Furthermore, studies of pre- and post-exposure prophylaxis are often segregated
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when in fact under conditions of ‘rapid containment’, as envisaged by WHO, it
will not be known if individuals within the containment zone are being given pre-
or post-exposure prophylaxis. We therefore undertook a systematic review and
meta-analysis according to the requirements of the Preferred Reporting Items for
Systematic Review and Meta-Analyses (PRISMA) statement [19], deliberately
combining data from pre- and post-exposure prophylaxis studies. We compared
our findings to previous systematic reviews and meta-analyses and discussed the
differences between our study and the previous studies.
Methods
The systematic review protocol was registered with the National Institute for
Health Research international prospective register of scientific reviews
(PROSPERO) prior to executing the literature search strategy [20]. The PRISMA
checklist is available as supporting information. The original study protocol was
amended to clarify the review questions and eligibility criteria.
We assessed the evidence in humans that treatment of influenza cases and
prophylaxis of their contacts reduce transmission. We considered all experimental
and observational studies. Previous systematic reviews and meta-analyses were
cross-referenced in order to identify the extent to which they had summarised all
the available data and to test the sensitivity of our literature search. The study
population was defined as persons of any age with laboratory confirmed influenza
infection (seasonal, pandemic or avian), or with influenza-like illness (ILI), or
those considered to have had close contact with any of the above persons.
Laboratory confirmation was defined as a respiratory specimen which tested
positive for influenza virus by reverse transcriptase-polymerase chain reaction
(RT-PCR) or viral culture [21]. Symptomatic ILI was defined as an acute
respiratory illness with onset during the last seven days with measured
temperature $38 C˚ and cough [22]. Close contact was defined as having cared
for, lived with, or had direct contact with respiratory or body fluids of person or
persons with laboratory confirmed influenza infection or symptomatic ILI [21].
The intervention studied was neuraminidase inhibitors (oseltamivir, zanamivir or
laninamivir) whether administered as capsules, suspensions or by oral inhalation.
Peramivir was not considered; being administered intravenously, it is unsuitable
for use at community level. Eligible comparators included no treatment, placebo,
or sham antivirals, although we also included studies which did not use a
comparator. The outcome measure was community transmission which, in the
absence of an internationally accepted definition of what constitutes a community
setting, we defined as: epidemiologically linked cases in settings other than
hospitals, care homes, nursing homes, boarding schools, and places of detention.
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Search strategy
One reviewer searched healthcare databases and other literature sources to
identify published and unpublished literature on human subjects, in any language,
up to December 2012 (see S1 Table: Literature search sources). The search was
based on the term construct used for MEDLINE described in the review protocol,
adapted for other literature sources where necessary (see S2 Table: Literature
search terms). Reference and citation tracking were undertaken to identify further
relevant studies. Relevant manufacturers (Roche, GlaxoSmithKline, and Biota
Holdings Ltd) and domain experts were contacted for possibly relevant literature
to screen for inclusion.
Study selection
Identified articles were imported into EndNote software X4.0.2 (Thomson
Reuters, California, USA) and screened by two reviewers after removal of
duplicates. The protocol eligibility criteria were applied using a three stage
sequential sifting approach to review title, abstract and full text [20]. Sifting was
performed in parallel by two reviewers (GNO, HEO), with any disagreements
discussed and resolved via involvement of a third reviewer (CRB).
Data extraction
Data extraction was carried out, in parallel, by two reviewers (GNO, HEO) using a
standardised, piloted template; a third reviewer (CRB) resolved any disagree-
ments. The data extraction form is available as an appendix to the study protocol
[20].
Risk of bias assessment
The risk of bias in individual studies was assessed at both the study and outcome
level in compliance with the PRISMA statement [19]. The risk of bias in
experimental and prospective cohort studies was assessed using the Cochrane
Collaboration tool [23]. The Newcastle Ottawa scale was used for assessing risk of
bias in other observational studies [24].
Result synthesis and analysis
A narrative approach was used to synthesise quality assessments according to a
recognised framework [25]. Sub-analyses were planned to describe differences
between: pre-exposure prophylaxis, post-exposure prophylaxis without treatment
of index case, post-exposure prophylaxis with treatment of index case, and
treatment of index case only; seasonal, pandemic and avian influenza; and
neuraminidase inhibitor type. Meta-analysis was conducted where feasible, using a
random effects model, in Stata version 12 (StatCorp LP, Texas, USA). Pooled
estimates of effect were calculated using odds ratios (OR) including 95%
confidence intervals (CIs). Statistical heterogeneity was assessed through
Neuraminidase Inhibitors for the Containment of Influenza
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calculation of I2. Sensitivity analyses were undertaken for RCTs of seasonal
influenza and observational studies of influenza A(H1N1)pdm09. Publication bias
was assessed for each outcome measure, visually using funnel plots of effect size
versus sample size for each included study, and statistically using Egger’s
regression test.
Results
A total of 13,994 records were identified from all sources. After removing
duplicates, 8,568 remained; sifting revealed 17 eligible studies (summarised in
Fig. 1). Table 1 shows a summary of characteristics of these 17 studies.
Summarised details of the included RCTs and observational studies, and of the
identified previous systematic reviews, are included as supporting information; S3
Table: Summary details of included RCTs (n59), S4 Table: Summary details of
included observational studies (n58), and S5 Table: Summary details of
identified previous systematic reviews (n57).
The RCTs (n59) [26–34] and observational studies (n58) [6, 35–41] involved
10,532 and 8,740 individuals respectively (total519,272). We found no articles on
avian influenza that met our study eligibility criteria. All retrieved articles were
either on oseltamivir, zanamivir or both. Of all studies, 12 (71%) evaluated
transmission in households or discrete household-type settings [6, 26, 27, 30, 33–
36, 38–41] and five (29%) evaluated individual transmission [28, 29, 31, 32, 37].
Risk of bias within studies
Fig. 2 and Table 2 show the overall risk of bias per domain or question for the
RCTs and observational studies. A high proportion of the RCTs was judged to be
at high or unclear risk of bias for sequence generation, allocation concealment,
blinding of outcome assessors and other sources of bias. However, most RCTs
were at a low risk of bias for blinding of participants and personnel, incomplete
outcome data and selective outcome reporting. The included prospective cohort
studies were judged to be at high risk of bias using the Cochrane Collaboration
tool while retrospective cohort studies were at low risk of bias within reporting
domains of the Newcastle Ottawa scale. Furthermore, nearly all RCTs and
observational studies presented additional risk of effect modification due to the
vaccination status of participants (with inclusion of both vaccinated and
unvaccinated participants). There were also variable proportions of comorbidities
in each study sample population.
Synthesis of results
Prophylaxis with oseltamivir
Four RCTs studied the use of oseltamivir for prophylaxis against laboratory
confirmed seasonal influenza [27–29, 34]; three studied post-exposure prophylaxis
[27, 29, 34], and one pre-exposure prophylaxis [28]. Oseltamivir was found to
Neuraminidase Inhibitors for the Containment of Influenza
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have 100% (p,0.001) [29], 68% (95% CI 34.9 to 84.2; p50.0017) [27], and 89%
(95% CI 67 to 97; p,0.001) [34] protective efficacy for individuals against
laboratory confirmed influenza when used post-exposure. For pre-exposure
prophylaxis, protective efficacy was 87% (95% CI 65 to 96; p,0.001) [28]. Post-
exposure prophylaxis against seasonal influenza provided statistically significant
protective efficacy of 58.5% and 84% for household contacts respectively [27, 34].
Six observational studies evaluated oseltamivir for post-exposure prophylaxis
against influenza A(H1N1)pdm09 [35–38, 40, 41] and one observational study
against seasonal influenza [6]. The secondary attack rate (SAR) among household
contacts was found to be lower in those given prophylaxis (0%) compared to
those not (8.5%). There was a significant reduction in influenza R0 from 1.91
(95% CI 1.50 to 2.36) before prophylactic intervention to 0.11 after intervention
(95% CI 0.05 to 0.20; Bayesian posterior hypothesis p,0.001) [37]. Meta-analysis
of oseltamivir prophylaxis for individual protection irrespective of study design,
influenza strain and combining pre- and post-exposure studies showed the pooled
odds of laboratory confirmed influenza was statistically significantly lower
Fig. 1. Summary of the literature search and sifting process (PRISMA flow diagram). CENTRAL5Cochrane Central Register of Controlled Trials;
CDSR5Cochrane Database of Systematic Reviews; DARE5Database of Abstracts of Reviews; NHS5National Health Services; HTA5Health Technology
Assessment; WHO Global Medical Index5World Health Organization Global Medical Index; OpenSIGLE5System for information on Grey Literature in
Europe; CDC5Centers for Diseases Control and Prevention; IFPMA5International Federation of Pharmaceutical Manufacturers Associations.
doi:10.1371/journal.pone.0113633.g001
Table 1. Characteristics of eligible studies (n517).
Study characteristics Number of studies
Study design
Randomised controlled trials [26–34] 9
Prospective cohort studies [6, 37, 38, 40, 41] 5
Other observational studies [35, 36, 39] 3
Setting
Household or household-type transmission [6, 26, 27, 30, 33–36, 38–41] 12
Individual transmission [28, 29, 31, 32, 37] 5
Mode of influenza infection
Natural means [6, 26–28, 30–41] 16
Artificial inoculation [29] 1
Influenza type
Seasonal [6, 26–34] 10 (A(H3N2), A(H1N1), B)
Pandemic [35–41] 7 (A(H1N1)pdm09)
Intervention (Neuraminidase inhibitor type)
Oseltamivir [6, 27–29, 34–38, 41] 10
Zanamivir [26, 30–33, 39] 6
Oseltamivir or zanamivir [40] 1
Specific study characteristics and the number of studies that possess each characteristic.
doi:10.1371/journal.pone.0113633.t001
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Fig. 2. Risk of bias assessment using the Cochrane Collaboration tool. Upper panel: RCTs and
prospective cohort studies (n514); Lower panel: RCTs only (n59).
doi:10.1371/journal.pone.0113633.g002
Table 2. Risk of bias assessment for observational studies (n53) excluding prospective cohort studies) using Newcastle Ottawa Quality Assessment Scale.
Study
Domain
Goldstein et al.
(2010)
Nishiura & Oshitani
(2011)
Fallo et al.
(2012)
Representativeness of the exposed cohort 3 3 3
Selection of the non-exposed cohort 3 3 3
Ascertainment of exposures 3 3 3
Demonstration that outcome of interest was not present at start of study 3 3 3
Comparability of cohorts on the basis of the design or analysis 7 3 7
Assessment of outcome 7 3 7
Was follow-up long enough for outcomes to occur 3 3 3
Adequacy of follow-up of cohorts 3 3 3
3 Denotes a score of 1 (domain assessment was satisfactory), 7 denotes no score (domain assessment was not satisfactory).
doi:10.1371/journal.pone.0113633.t002
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compared to placebo or no therapy (n58 studies [27–29, 34, 35, 37, 38, 41];
OR50.11; 95% CI 0.06 to 0.20; p,0.001; I2558.7%; see Fig. 3).
Sensitivity analyses of the oseltamivir data demonstrated pooled estimates for
individual protection comparable to the primary analysis for experimental studies
of seasonal influenza (n54 studies [27–29, 34]; OR50.15; 95% CI 0.07 to 0.33;
p,0.001; I2537.3%) and observational studies of influenza A(H1N1)pdm09
(n54 studies [35, 37, 38, 41]; OR50.09; 95% CI 0.04 to 0.19; p,0.001;
I2561.7%). Meta-analysis of prophylaxis with oseltamivir against seasonal
influenza for household protection also showed statistically significantly lower
pooled odds of laboratory confirmed influenza compared to placebo or no
therapy (n52 studies [27, 34]; OR50.23; 95% CI 0.09 to 0.59; p,0.002;
I2539.0%; see Fig. 4).
Prophylaxis with zanamivir
There were five RCTs on zanamivir, all on seasonal influenza [26, 30–33]. Three of
these reported data on individual protection [30–32], and one study each reported
data on household protection [26], and both individual and household protection
[33]. Zanamivir was found to have a protective efficacy of 83% and 84% for
individuals against seasonal influenza with pre-exposure prophylaxis for 28 days
(p,0.001) [31, 32]. Zanamivir was also found to have a protective efficacy of 82%
(p,0.001) for individuals after 10 days post-exposure prophylaxis against
seasonal influenza, and 73% protective efficacy (p50.058) after five days post-
exposure prophylaxis [30, 33]. Zanamivir prophylaxis for 10 days was found to
have a protective efficacy of 72% and 81% for households, with both results
Fig. 3. Meta-analysis of pre- and post-exposure prophylaxis with oseltamivir against seasonal and
influenza A(H1N1)pdm09 (Individual protection). Horizontal axis represent odds ratio; Columns represent
study authors and year of publication, effect size including pooled estimate of effect, and 95% CI, and the
weighting of each study in the meta-analysis.
doi:10.1371/journal.pone.0113633.g003
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statistically significant (p,0.001). Meta-analysis of prophylaxis for individual
protection with zanamivir (combined pre- and post-exposure prophylaxis)
showed the pooled odds of laboratory confirmed influenza was statistically
significantly lower compared to placebo or no therapy (n54 studies [30–33];
OR50.23; 95% CI 0.16 to 0.35; p,0.001; I250.0%; see Fig. 5). Similarly, meta-
analysis of prophylaxis with zanamivir against seasonal influenza for household
protection also showed the pooled odds of laboratory confirmed influenza was
statistically significantly lower compared to placebo or no therapy (n52 studies
[26, 33]; OR50.18; 95% CI50.10 to 0.31; p,0.001; I250.0%; see Fig. 6).
Treatment of index case alone with either oseltamivir or zanamivir
One observational study of 1547 households found that use of oseltamivir or
zanamivir for treatment of an index case offered 43% (95% CI 27 to 56%) and
42% (95% CI 14 to 62%) household protection against secondary cases when the
index case was treated within 24 hours or within 24 to 48 hours of symptom onset
respectively (p value not given) [39].
Risk of bias across studies
We did not identify evidence of publication bias in any of the meta-analyses we
carried out.
Discussion
There have been controversies surrounding the evidence base on the effectiveness
of neuraminidase inhibitors for influenza prevention and treatment. The recent
Cochrane Collaboration review on published and unpublished data from only
Fig. 4. Meta-analysis of prophylaxis for households with oseltamivir against seasonal influenza.
Horizontal axis represent odds ratio; Columns represent study authors and year of publication, effect size
including pooled estimate of effect, and 95% CI, and the weighting of each study in the meta-analysis.
doi:10.1371/journal.pone.0113633.g004
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RCTs mainly in healthy individuals with mild illnesses due to seasonal influenza
recommended a review of the guidance on using neuraminidase inhibitors based
on the findings of small benefit of treatment compared with the risk of harm; [14]
nevertheless the same review concludes that prophylactic use reduces the risk of
developing symptomatic influenza. We felt it was important to include
observational data, including that generated during the 2009–10 pandemic period
which potentially inform clinical and public health practice. In addition we felt
Fig. 5. Meta-analysis of pre- and post-exposure prophylaxis with zanamivir against seasonal influenza
(individual protection). Horizontal axis represent odds ratio; Columns represent study authors and year of
publication, effect size including pooled estimate of effect, and 95% CI, and the weighting of each study in the
meta-analysis.
doi:10.1371/journal.pone.0113633.g005
Fig. 6. Meta-analysis of prophylaxis for households with zanamivir against seasonal influenza.
Horizontal axis represent odds ratio; Columns represent study authors and year of publication, effect size
including pooled estimate of effect, and 95% CI, and the weighting of each study in the meta-analysis.
doi:10.1371/journal.pone.0113633.g006
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that the amalgamation of data on pre- and post-exposure use better suited the
circumstances under which neuraminidase inhibitors might be used in a WHO
Rapid Containment response setting. Our results suggest that zanamivir and
oseltamivir are both effective as prophylaxis for individuals and households
against laboratory confirmed seasonal influenza and influenza A(H1N1)pdm09
infection, irrespective of modality of usage (pre-exposure or post-exposure). We
did not find any data reporting on the effectiveness of prophylaxis for a wider
population group or for newer neuraminidase inhibitors. It is important to
recognise that the WHO Rapid Containment Protocol anticipates that all (or
almost all) asymptomatic residents of a population will be given neuraminidase
inhibitor prophylaxis for 20 days. This will be an emergency measure, undertaken
without drawing any distinction between those exposed (post-exposure
prophylaxis) and unexposed (pre-exposure prophylaxis) within the containment
zone; in effect a mixture of pre-exposure and post-exposure prophylaxis in
unknown proportions. Therefore combining data on studies of pre- and post-
exposure prophylaxis, as we have done in this review, offers the most meaningful
estimate of effectiveness in the contest of the Rapid Containment Protocol and
similar emergency public health control interventions in community settings. To
our knowledge, it is the first systematic review to take such an approach.
Our data are broadly consistent with the findings from RCTs in the latest
Cochrane Collaboration review on prophylaxis against symptomatic influenza
[14], even though the two datasets are not fully overlapping in terms of RCTs
included and the Cochrane review did not consider observational studies.
Although we did not identify evidence of publication bias in any of the meta-
analyses carried out, we cannot fully exclude this because there were relatively few
studies available. It should also be noted that 37.5% of included oseltamivir
studies and 50% of zanamivir studies respectively, emanated from essentially the
same group of investigators for each drug; and all RCTs were sponsored by the
respective manufacturers. Some caution is therefore needed during interpretation.
Overall our estimates of protection are highly consistent with those obtained by
previous reviews. Cooper et al. 2003 reviewed two RCTs each on oseltamivir and
zanamivir, and found a 70% to 90% reduction in odds of individuals developing
laboratory confirmed influenza with oseltamivir or zanamivir as post-exposure
prophylaxis. They showed a protective efficacy of 74% (95% CI 16 to 92%) for
individuals with oseltamivir or zanamivir, 81% (95% CI 62% to 91%) with
zanamivir for households and 90% (95% CI 71% to 96%) with oseltamivir for
households. Langley and Faughnan 2004 reviewed six RCTs on oseltamivir and
zanamivir, and found a reduced rate of laboratory confirmed influenza ranging
from 18% to 67% in the placebo group to 3.6% to 38% in the chemoprophylaxis
group. Jefferson et al. 2006 reviewed six RCTs and reported a 62% (95% CI 15% to
83%) protective efficacy with zanamivir for individuals, and 61% (95% CI 15% to
82%) and 73% (95% CI 33% to 89%) protective efficacy with 75 mg and 150 mg
oseltamivir respectively (the latter being not the licensed dosage), for individuals
against laboratory confirmed influenza. Jefferson et al. 2009 reviewed two RCTs
each for oseltamivir and zanamivir, and found a protective efficacy of 62% (95% CI
Neuraminidase Inhibitors for the Containment of Influenza
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15% to 83%) for individuals using zanamivir, and 61% (95% CI 15% to 82%) for
oseltamivir when given as post-exposure prophylaxis against laboratory confirmed
influenza. Shun-Shin et al. 2009 and Wang et al. 2012 reviewed three RCTs each
and found an 8% absolute reduction in laboratory confirmed influenza with both
zanamivir and oseltamivir prophylaxis. Jackson et al. 2011 reviewed two and three
RCTs for oseltamivir and zanamivir respectively and showed a household protective
efficacy of 81% (95% CI 55% to 92%) for oseltamivir, and 79% (95% CI 67% to
87%) for zanamivir against symptomatic laboratory confirmed influenza. All the
RCTs included in the above previous systematic reviews form part of this present
review; but individually, previous systematic reviews did not include all the RCTs.
Therefore our review includes the largest number of RCTs.
In all previous systematic reviews, oseltamivir and zanamivir were compared
against placebo using RCT designs. In our opinion, observational studies also
form part of a comprehensive evaluation, especially since further evidence was
generated during the 2009 pandemic when RCT designs were, in general, ethically
unfeasible. Therefore inclusion of observational studies from large populations
during pandemic periods, as we have done, may provide estimates that are more
relevant for pandemic policy makers. It should be noted that the Rapid
Containment Protocol is aimed at preventing influenza transmission in a large
geographically cordoned population of typically over one million people.
However, this contrasts sharply with the evidence base, which we found mainly
restricted to household level studies. A smaller number of non-household studies,
for example in military barracks and university community settings, also met our
definition of community transmission but nevertheless these were still highly
restricted examples, compared with the community transmission scenario
envisaged in the Rapid Containment Protocol.
Studies included in this review varied in methodology including the participants
selection criteria, influenza type, virus strain and virulence (in challenge studies),
intervention type, dose and administration strategy, duration of intervention,
comparators, study settings, and characteristics of study participants and rate of
compliance. Variations in participants’ age distribution, gender, influenza
vaccination status and comorbidities were judged to pose potential risks of
heterogeneity within the same study types. In particular, we acknowledge that
variations in participants’ influenza vaccination status could be an effect modifier in
many of the studies, mostly observational, which lacked clarity on vaccination status
of the study populations. In reality, under a rapid containment scenario, it is most
likely that the population would be unvaccinated against the emerging virus.
Information regarding sample size calculation was found to be lacking in many
studies and among those providing such information, there were differences in the
assumptions made for the calculation. Some studies were randomised by individual
[28–32], while others were randomised by household [26, 27, 33, 34]. Variation in
treatment compliance between studies is a potential limitation. While 98%
compliance was reported in some studies [26–28], this information was not
provided in many others. Compliance may also be an issue during any ‘real-life’
rapid containment operation.
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A unique study evaluated the impact of ring chemoprophylaxis with oseltamivir
on transmission of influenza A(H1N1)pdm09 and found a significant reduction
in SAR from 6.4% before prophylaxis to 0.6% afterwards [37]. However, the study
setting was a semi-closed military camp in Singapore, where strict adherence to
directives and high compliance rate are both expected. Measures such as
quarantine, treatment of infected individuals, and restriction of movement were
also implemented. These would however be more difficult to actualise in a
heterogeneous civilian population. Reduction of influenza spread is often given as
a rationale for treatment of infected individuals. However, only one study on
treatment of the index case alone met our criteria for inclusion. This study was
observational, and evaluated household protection against laboratory confirmed
influenza with the use of oseltamivir or zanamivir.
To adequately inform public health policy on influenza containment, it is
necessary to evaluate all population-wide experimental and observational studies
on the impact of neuraminidase inhibitors on seasonal, pandemic and avian
influenza transmission, which this systematic review has sought to do. However,
while it provides substantial evidence for oseltamivir and zanamivir effectiveness
for individual and household prophylaxis, we did not identify direct evidence to
confirm or refute the impact of neuraminidase inhibitors on community
transmission in wider population settings.
Conclusion
There is strong evidence that the neuraminidase inhibitors oseltamivir and
zanamivir are effective as prophylaxis for individuals and households irrespective
of modality of use (pre- and post-exposure) and treatment of the index case (or
not). Beyond household settings, the evidence base is much more limited. We
found no data which directly support an effect on community transmission as
envisaged by the WHO Rapid Containment Protocol.
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